PTPRC and neoplasm: The proportions of tumor cells in comparison to major stromal cell subsets (CD45+ immune cells, fibroblasts, endothelial cells) were not significantly changed, although, as expected, there was a tendency of reduced tumor cell abundance in anti-BTLA antibody treated tumors (Figure 3B).